<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39392236</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1600-0897</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>American journal of reproductive immunology (New York, N.Y. : 1989)</Title><ISOAbbreviation>Am J Reprod Immunol</ISOAbbreviation></Journal><ArticleTitle>COVID-19 Vaccine mRNA Biodistribution: Maternal and Fetal Exposure Risks.</ArticleTitle><Pagination><StartPage>e13934</StartPage><MedlinePgn>e13934</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/aji.13934</ELocationID><Abstract><AbstractText>SARS-CoV-2 infection during pregnancy has severe consequences on maternal and neonatal health. Presently, vaccination stands as a critical preventive measure for mitigating infection-related risks. Although the initial clinical trials for the COVID-19 vaccines excluded pregnant women, subsequent investigations have indicated mRNA vaccinations' effectiveness and short-term safety during pregnancy. However, there is a lack of information regarding the potential biodistribution of the vaccine mRNA during pregnancy and lactation. Recent findings indicate that COVID-19 vaccine mRNA has been detected in breast milk, suggesting that its presence is not confined to the injection site and raises the possibility of similar distribution to the placenta and the fetus. Furthermore, the potential effects and responses of the placenta and fetus to the vaccine mRNA are still unknown. While potential risks might exist with the exposure of the placenta and fetus to the COVID-19 mRNA vaccine, the application of mRNA therapies for maternal and fetal conditions offers a groundbreaking prospect. Future research should leverage the unique opportunity provided by the first-ever application of mRNA vaccines in humans to understand their biodistribution and impact on the placenta and fetus in pregnant women. Such insights could substantially advance the development of safer and more effective future mRNA-based therapies during pregnancy.</AbstractText><CopyrightInformation>© 2024 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Connie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>New York University-Grossman Long Island School of Medicine, Mineola, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Koral</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>New York University-Grossman Long Island School of Medicine, Mineola, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Xinhua</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Women and Children's Research Laboratory, Departments of Foundations of Medicine, New York University-Grossman Long Island School of Medicine, Mineola, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiller</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>New York University-Grossman Long Island School of Medicine, Mineola, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Surendra</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4331-3467</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanna</LastName><ForeName>Nazeeh</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-2167-5712</Identifier><AffiliationInfo><Affiliation>Women and Children's Research Laboratory, Departments of Foundations of Medicine, New York University-Grossman Long Island School of Medicine, Mineola, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Neonatology, New York University Langone Hospital-Long Island, New York University-Grossman Long Island School of Medicine, Mineola, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1R01HD098258</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HD110408</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AI141501</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Am J Reprod Immunol</MedlineTA><NlmUniqueID>8912860</NlmUniqueID><ISSNLinking>1046-7408</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000087503">mRNA Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005333" MajorTopicYN="Y">Fetus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010920" MajorTopicYN="Y">Placenta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011251" MajorTopicYN="Y">Pregnancy Complications, Infectious</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087503" MajorTopicYN="N">mRNA Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008895" MajorTopicYN="N">Milk, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">biodistribution</Keyword><Keyword MajorTopicYN="N">lipid nanoparticles</Keyword><Keyword MajorTopicYN="N">neonate</Keyword><Keyword MajorTopicYN="N">placenta</Keyword><Keyword MajorTopicYN="N">pregnancy</Keyword><Keyword MajorTopicYN="N">vaccine mRNA</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>8</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39392236</ArticleId><ArticleId IdType="doi">10.1111/aji.13934</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>C. Chakraborty, A. R. Sharma, M. Bhattacharya, and S. S. Lee, “From COVID‐19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape,” Frontiers in Immunology 12 (2021): 679344, https://doi.org/10.3389/fimmu.2021.679344.</Citation></Reference><Reference><Citation>N. Hanna, M. Hanna, and S. Sharma, “Is Pregnancy an Immunological Contributor to Severe or Controlled COVID‐19 Disease?,” American Journal of Reproductive Immunology 84, no. 5 (2020): e13317, https://doi.org/10.1111/aji.13317.</Citation></Reference><Reference><Citation>L. Schoenmaker, D. Witzigmann, J. A. Kulkarni, et al., “mRNA‐Lipid Nanoparticle COVID‐19 Vaccines: Structure and Stability,” International Journal of Pharmaceutics 601 (2021): 120586, https://doi.org/10.1016/j.ijpharm.2021.120586.</Citation></Reference><Reference><Citation>J. Benevent, S. Khettar, and I. Lacroix, “COVID‐19 Vaccines and Pregnancy: What Do We Know?,” Therapie 76, no. 4 (2021): 373–374, https://doi.org/10.1016/j.therap.2021.05.011.</Citation></Reference><Reference><Citation>CDC: COVID‐19 Vaccination for People Who Are Pregnant or Breastfeeding, https://www.cdc.gov/covid/vaccines/pregnant‐or‐breastfeeding.html#:~:text=Everyone%20ages%206%20months%20and,pregnancy%20is%20safe%20and%20effective.</Citation></Reference><Reference><Citation>S. Ayhan, D. Oluklu, A. Atalay, et al., “COVID‐19 Vaccine Acceptance in Pregnant Women,” International Journal of Gynaecology and Obstetrics 154, no. 2 (2021): 291–296, https://doi.org/10.1002/ijgo.13713.</Citation></Reference><Reference><Citation>E. H. Pilkington, E. J. A. Suys, N. L. Trevaskis, et al., “From Influenza to COVID‐19: Lipid Nanoparticle mRNA Vaccines at the Frontiers of Infectious Diseases,” Acta Biomaterialia 131 (2021): 16–40, https://doi.org/10.1016/j.actbio.2021.06.023.</Citation></Reference><Reference><Citation>F. P. Polack, S. J. Thomas, N. Kitchin, et al., “Safety and Efficacy of the BNT162b2 mRNA Covid‐19 Vaccine,” New England Journal of Medicine 383, no. 27 (2020): 2603–2615, https://doi.org/10.1056/NEJMoa2034577.</Citation></Reference><Reference><Citation>L. R. Baden, H. M. El Sahly, B. Essink, et al., “Efficacy and Safety of the mRNA‐1273 SARS‐CoV‐2 Vaccine,” New England Journal of Medicine 384, no. 5 (2021): 403–416, https://doi.org/10.1056/NEJMoa2035389.</Citation></Reference><Reference><Citation>Q. Cheng, T. Wei, L. Farbiak, L. T. Johnson, S. A. Dilliard, and D. J. Siegwart, “Selective Organ Targeting (SORT) Nanoparticles for Tissue‐Specific mRNA Delivery and CRISPR‐Cas Gene Editing,” Nature Nanotechnology 15, no. 4 (2020): 313–320, https://doi.org/10.1038/s41565‐020‐0669‐6.</Citation></Reference><Reference><Citation>C. Muoth, L. Aengenheister, M. Kucki, P. Wick, and T. Buerki‐Thurnherr, “Nanoparticle Transport Across the Placental Barrier: Pushing the Field Forward!,” Nanomedicine (London) 11, no. 8 (2016): 941–957, https://doi.org/10.2217/nnm‐2015‐0012.</Citation></Reference><Reference><Citation>N. Aliakbarinodehi, A. Gallud, M. Mapar, et al., “Interaction Kinetics of Individual mRNA‐Containing Lipid Nanoparticles With an Endosomal Membrane Mimic: Dependence on pH, Protein Corona Formation, and Lipoprotein Depletion,” ACS Nano 16, no. 12 (2022): 20163–20173, https://doi.org/10.1021/acsnano.2c04829.</Citation></Reference><Reference><Citation>W. Xiao and H. Gao, “The Impact of Protein Corona on the Behavior and Targeting Capability of Nanoparticle‐Based Delivery System,” International Journal of Pharmaceutics 552, no. 1 (2018): 328–339, https://doi.org/10.1016/j.ijpharm.2018.10.011.</Citation></Reference><Reference><Citation>M. H. Akhter, H. Khalilullah, M. Gupta, et al., “Impact of Protein Corona on the Biological Identity of Nanomedicine: Understanding the Fate of Nanomaterials in the Biological Milieu,” Biomedicines 9, no. 10 (2021), 1496, https://doi.org/10.3390/biomedicines9101496.</Citation></Reference><Reference><Citation>T. Kopac, “Protein Corona, Understanding the Nanoparticle‐Protein Interactions and Future Perspectives: A Critical Review,” International Journal of Biological Macromolecules 169 (2021): 290–301, https://doi.org/10.1016/j.ijbiomac.2020.12.108.</Citation></Reference><Reference><Citation>S. Tinari, “The EMA Covid‐19 Data Leak, and What It Tells Us About mRNA Instability,” British Medical Journal 372 (2021): n627, https://doi.org/10.1136/bmj.n627.</Citation></Reference><Reference><Citation>European Medicines Agency. (2021). Assessment Report: COVID‐19 Vaccine Moderna. Procedure No. EMEA/H/C/005791/0000. Netherlands: EMA, https://www.ema.europa.eu/en/documents/assessment‐report/spikevax‐previously‐covid‐19‐vaccine‐moderna‐epar‐public‐assessment‐report_en.pdf.</Citation></Reference><Reference><Citation>European Medicines Agency. (2021). Assessment Report: Comirnaty, COVID‐19 mRNA Vaccine (Nucleoside‐Modified). Procedure No. EMEA/H/C/005735/0000. Netherlands: EMA, https://www.ema.europa.eu/en/documents/assessment‐report/comirnaty‐epar‐public‐assessment‐report_en.pdf.</Citation></Reference><Reference><Citation>P. Doshi, “Will Covid‐19 Vaccines Save Lives? Current Trials Aren't Designed to Tell Us,” British Medical Journal 371 (2020): m4037, https://doi.org/10.1136/bmj.m4037.</Citation></Reference><Reference><Citation>M. L. Bondi, R. Di Gesu, and E. F. Craparo, “Lipid Nanoparticles for Drug Targeting to the Brain,” Methods in Enzymology 508 (2012): 229–251, https://doi.org/10.1016/B978‐0‐12‐391860‐4.00012‐4.</Citation></Reference><Reference><Citation>N. Hanna, A. Heffes‐Doon, X. Lin, et al., “Detection of Messenger RNA COVID‐19 Vaccines in Human Breast Milk,” JAMA Pediatrics 176, no. 12 (2022): 1268–1270, https://doi.org/10.1001/jamapediatrics.2022.3581.</Citation></Reference><Reference><Citation>N. Pardi, S. Tuyishime, H. Muramatsu, et al., “Expression Kinetics of Nucleoside‐Modified mRNA Delivered in Lipid Nanoparticles to Mice by Various Routes,” Journal of Controlled Release 217 (2015): 345–351, https://doi.org/10.1016/j.jconrel.2015.08.007.</Citation></Reference><Reference><Citation>K. Bahl, J. J. Senn, O. Yuzhakov, et al., “Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines Against H10N8 and H7N9 Influenza Viruses,” Molecular Therapy 25, no. 6 (2017): 1316–1327, https://doi.org/10.1016/j.ymthe.2017.03.035.</Citation></Reference><Reference><Citation>A. J. Krauson, F. V. C. Casimero, Z. Siddiquee, and J. R. Stone, “Duration of SARS‐CoV‐2 mRNA Vaccine Persistence and Factors Associated With Cardiac Involvement in Recently Vaccinated Patients,” NPJ Vaccines 8, no. 1 (2023): 141, https://doi.org/10.1038/s41541‐023‐00742‐7.</Citation></Reference><Reference><Citation>K. Roltgen, S. C. A. Nielsen, O. Silva, et al., “Immune Imprinting, Breadth of Variant Recognition, and Germinal Center Response in Human SARS‐CoV‐2 Infection and Vaccination,” Cell 185, no. 6 (2022): 1025–1040.e1014, https://doi.org/10.1016/j.cell.2022.01.018.</Citation></Reference><Reference><Citation>T. E. Fertig, L. Chitoiu, D. S. Marta, et al., “Vaccine mRNA Can Be Detected in Blood at 15 Days Post‐Vaccination,” Biomedicines 10, no. 7 (2022), 1538, https://doi.org/10.3390/biomedicines10071538.</Citation></Reference><Reference><Citation>S. Bansal, S. Perincheri, T. Fleming, et al., “Cutting Edge: Circulating Exosomes With COVID Spike Protein Are Induced by BNT162b2 (Pfizer‐BioNTech) Vaccination Prior to Development of Antibodies: A Novel Mechanism for Immune Activation by mRNA Vaccines,” Journal of Immunology 207, no. 10 (2021): 2405–2410, https://doi.org/10.4049/jimmunol.2100637.</Citation></Reference><Reference><Citation>M. Maugeri, M. Nawaz, A. Papadimitriou, et al., “Linkage Between Endosomal Escape of LNP‐mRNA and Loading Into EVs for Transport to Other Cells,” Nature Communications 10, no. 1 (2019): 4333, https://doi.org/10.1038/s41467‐019‐12275‐6.</Citation></Reference><Reference><Citation>K. L. Swingle, H. C. Safford, H. C. Geisler, et al., “Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta During Pregnancy,” Journal of the American Chemical Society 145, no. 8 (2023): 4691–4706, https://doi.org/10.1021/jacs.2c12893.</Citation></Reference><Reference><Citation>V. Kulvietis, V. Zalgeviciene, J. Didziapetriene, and R. Rotomskis, “Transport of Nanoparticles Through the Placental Barrier,” The Tohoku Journal of Experimental Medicine 225, no. 4 (2011): 225–234, https://doi.org/10.1620/tjem.225.225.</Citation></Reference><Reference><Citation>P. Wick, A. Malek, P. Manser, et al., “Barrier Capacity of Human Placenta for Nanosized Materials,” Environmental Health Perspectives 118, no. 3 (2010): 432–436, https://doi.org/10.1289/ehp.0901200.</Citation></Reference><Reference><Citation>P. K. Myllynen, M. J. Loughran, C. V. Howard, R. Sormunen, A. A. Walsh, and K. H. Vahakangas, “Kinetics of Gold Nanoparticles in the Human Placenta,” Reproductive Toxicology 26, no. 2 (2008): 130–137, https://doi.org/10.1016/j.reprotox.2008.06.008.</Citation></Reference><Reference><Citation>R. Tenchov, R. Bird, A. E. Curtze, and Q. Zhou, “Lipid Nanoparticles Horizontal Line From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement,” ACS Nano 15, no. 11 (2021): 16982–17015, https://doi.org/10.1021/acsnano.1c04996.</Citation></Reference><Reference><Citation>R. E. Young, K. M. Nelson, S. I. Hofbauer, et al., “Systematic Development of Ionizable Lipid Nanoparticles for Placental mRNA Delivery Using a Design of Experiments Approach,” Bioactive Materials 34 (2024): 125–137, https://doi.org/10.1016/j.bioactmat.2023.11.014.</Citation></Reference><Reference><Citation>N. Hanna, C. M. De Mejia, A. Heffes‐Doon, et al., “Biodistribution of mRNA COVID‐19 Vaccines in Human Breast Milk,” EBioMedicine 96 (2023): 104800, https://doi.org/10.1016/j.ebiom.2023.104800.</Citation></Reference><Reference><Citation>Y. Suzuki and H. Ishihara, “Difference in the Lipid Nanoparticle Technology Employed in Three Approved siRNA (Patisiran) and mRNA (COVID‐19 Vaccine) Drugs,” Drug Metabolism and Pharmacokinetics 41 (2021): 100424, https://doi.org/10.1016/j.dmpk.2021.100424.</Citation></Reference><Reference><Citation>L. Czernek and M. Duchler, “Exosomes as Messengers Between Mother and Fetus in Pregnancy,” International Journal of Molecular Sciences 21, no. 12 (2020), 4264, https://doi.org/10.3390/ijms21124264.</Citation></Reference><Reference><Citation>S. Sheller‐Miller, K. Choi, C. Choi, and R. Menon, “Cyclic‐Recombinase‐Reporter Mouse Model to Determine Exosome Communication and Function During Pregnancy,” American Journal of Obstetrics and Gynecology 221, no. 5 (2019): 502 e501–502 e512, https://doi.org/10.1016/j.ajog.2019.06.010.</Citation></Reference><Reference><Citation>M. C. Shepherd, E. Radnaa, O. A. Tantengco, et al., “Extracellular Vesicles From Maternal Uterine Cells Exposed to Risk Factors Cause Fetal Inflammatory Response,” Cell Communication and Signaling 19, no. 1 (2021): 100, https://doi.org/10.1186/s12964‐021‐00782‐3.</Citation></Reference><Reference><Citation>A. Santos, M. Sauer, A. J. Neil, et al., “Absence of SARS‐CoV‐2 Spike Glycoprotein Expression in Placentas From Individuals After mRNA SARS‐CoV‐2 Vaccination,” Modern Pathology 35, no. 9 (2022): 1175–1180, https://doi.org/10.1038/s41379‐022‐01061‐3.</Citation></Reference><Reference><Citation>M. Prahl, Y. Golan, A. G. Cassidy, et al., “Evaluation of Transplacental Transfer of mRNA Vaccine Products and Functional Antibodies During Pregnancy and Infancy,” Nature Communications 13, no. 1 (2022): 4422, https://doi.org/10.1038/s41467‐022‐32188‐1.</Citation></Reference><Reference><Citation>V. J. Gonzalez, L. Li, S. Buarpung, M. Prahl, J. F. Robinson, and S. L. Gaw, “Minimal mRNA Uptake and Inflammatory Response to COVID‐19 mRNA Vaccine Exposure in Human Placental Explants,” Iscience 26, no. 9 (2023): 107549, https://doi.org/10.1016/j.isci.2023.107549.</Citation></Reference><Reference><Citation>X. Lin, B. Botros, M. Hanna, et al., “Transplacental Transmission of the COVID‐19 Vaccine Messenger RNA: Evidence From Placental, Maternal, and Cord Blood Analyses Postvaccination,” American Journal of Obstetrics and Gynecology 230 (2024), e113–e116, https://doi.org/10.1016/j.ajog.2024.01.022.</Citation></Reference><Reference><Citation>T. Suo, X. Liu, J. Feng, et al., “ddPCR: A More Accurate Tool for SARS‐CoV‐2 Detection in Low Viral Load Specimens,” Emerging Microbes &amp; Infections 9, no. 1 (2020): 1259–1268, https://doi.org/10.1080/22221751.2020.1772678.</Citation></Reference><Reference><Citation>R. S. Riley, M. V. Kashyap, M. M. Billingsley, et al., “Ionizable Lipid Nanoparticles for In Utero mRNA Delivery,” Science Advances 7, no. 3 (2021), eaba1028, https://doi.org/10.1126/sciadv.aba1028.</Citation></Reference><Reference><Citation>H. Valadi, K. Ekstrom, A. Bossios, M. Sjostrand, J. J. Lee, and J. O. Lotvall, “Exosome‐Mediated Transfer of mRNAs and microRNAs is a Novel Mechanism of Genetic Exchange Between Cells,” Nature Cell Biology 9, no. 6 (2007): 654–659, https://doi.org/10.1038/ncb1596.</Citation></Reference><Reference><Citation>J. Miranda, C. Paules, S. Nair, et al., “Placental Exosomes Profile in Maternal and Fetal Circulation in Intrauterine Growth Restriction—Liquid Biopsies to Monitoring Fetal Growth,” Placenta 64 (2018): 34–43, https://doi.org/10.1016/j.placenta.2018.02.006.</Citation></Reference><Reference><Citation>L. Jia, X. Zhou, X. Huang, et al., “Maternal and Umbilical Cord Serum‐Derived Exosomes Enhance Endothelial Cell Proliferation and Migration,” Faseb Journal 32, no. 8 (2018): 4534–4543, https://doi.org/10.1096/fj.201701337RR.</Citation></Reference><Reference><Citation>L. Shen, Y. Li, R. Li, et al., “Placenta‑Associated Serum Exosomal miR‑155 Derived From Patients With Preeclampsia Inhibits eNOS Expression in Human Umbilical Vein Endothelial Cells,” International Journal of Molecular Medicine 41, no. 3 (2018): 1731–1739, https://doi.org/10.3892/ijmm.2018.3367.</Citation></Reference><Reference><Citation>H. Banoun, “Current State of Knowledge on the Excretion of mRNA and Spike Produced by Anti‐COVID‐19 mRNA Vaccines; Possibility of Contamination of the Entourage of Those Vaccinated by These Products,” Infectious Diseases Research 3, no. 4 (2022): 22, https://doi.org/10.53388/IDR20221125022.</Citation></Reference><Reference><Citation>B. B. Dugershaw, L. Aengenheister, S. S. K. Hansen, K. S. Hougaard, and T. Buerki‐Thurnherr, “Recent Insights on Indirect Mechanisms in Developmental Toxicity of Nanomaterials,” Particle and Fibre Toxicology 17, no. 1 (2020): 31, https://doi.org/10.1186/s12989‐020‐00359‐x.</Citation></Reference><Reference><Citation>B. K. Estep, C. J. Kuhlmann, S. Osuka, et al., “Skewed Fate and Hematopoiesis of CD34(+) HSPCs in Umbilical Cord Blood Amid the COVID‐19 Pandemic,” Iscience 25, no. 12 (2022): 105544, https://doi.org/10.1016/j.isci.2022.105544.</Citation></Reference><Reference><Citation>M. Khalifeh, L. G. Rubin, D. Dayya, et al., “SARS‐CoV‐2 Neutralizing Antibody Titers in Maternal Blood, Umbilical Cord Blood, and Breast Milk,” Journal of Perinatology 44, no. 1 (2024): 28–34, https://doi.org/10.1038/s41372‐023‐01843‐w.</Citation></Reference><Reference><Citation>R. C. Boelig, S. Chaudhury, Z. H. Aghai, et al., “Comprehensive Serologic Profile and Specificity of Maternal and Neonatal Cord Blood SARS‐CoV‐2 Antibodies,” AJOG Global Reports 2, no. 1 (2022): 100046, https://doi.org/10.1016/j.xagr.2021.100046.</Citation></Reference><Reference><Citation>S. Seneff, G. Nigh, A. M. Kyriakopoulos, and P. A. McCullough, “Innate Immune Suppression by SARS‐CoV‐2 mRNA Vaccinations: The Role of G‐Quadruplexes, Exosomes, and MicroRNAs,” Food and Chemical Toxicology 164 (2022): 113008, https://doi.org/10.1016/j.fct.2022.113008.</Citation></Reference><Reference><Citation>B. K. Patterson, E. B. Francisco, R. Yogendra, et al., “Persistence of SARS CoV‐2 S1 Protein in CD16+ Monocytes in Post‐Acute Sequelae of COVID‐19 (PASC) up to 15 Months Post‐Infection,” Frontiers in Immunology 12 (2021): 746021, https://doi.org/10.3389/fimmu.2021.746021.</Citation></Reference><Reference><Citation>S. Khan, M. S. Shafiei, C. Longoria, J. W. Schoggins, R. C. Savani, and H. Zaki, “SARS‐CoV‐2 Spike Protein Induces Inflammation via TLR2‐Dependent Activation of the NF‐kappaB Pathway,” Elife 10 (2021), e68563, https://doi.org/10.7554/eLife.68563.</Citation></Reference><Reference><Citation>J. P. Robles, M. Zamora, E. Adan‐Castro, L. Siqueiros‐Marquez, G. Martinez de la Escalera, and C. Clapp, “The Spike Protein of SARS‐CoV‐2 Induces Endothelial Inflammation Through Integrin Alpha5Beta1 and NF‐kappaB Signaling,” Journal of Biological Chemistry 298, no. 3 (2022): 101695, https://doi.org/10.1016/j.jbc.2022.101695.</Citation></Reference><Reference><Citation>W. A. Banks, P. Sharma, K. M. Bullock, K. M. Hansen, N. Ludwig, and T. L. Whiteside, “Transport of Extracellular Vesicles Across the Blood‐Brain Barrier: Brain Pharmacokinetics and Effects of Inflammation,” International Journal of Molecular Sciences 21, no. 12 (2020), 4407, https://doi.org/10.3390/ijms21124407.</Citation></Reference><Reference><Citation>F. Scholkmann and C. A. May, “COVID‐19, Post‐Acute COVID‐19 Syndrome (PACS, “Long COVID”) and Post‐COVID‐19 Vaccination Syndrome (PCVS, “Post‐COVIDvac‐Syndrome”): Similarities and Differences,” Pathology, Research and Practice 246 (2023): 154497, https://doi.org/10.1016/j.prp.2023.154497.</Citation></Reference><Reference><Citation>M. T. J. Halma, C. Plothe, P. Marik, and T. A. Lawrie, “Strategies for the Management of Spike Protein‐Related Pathology,” Microorganisms 11, no. 5 (2023), 1308, https://doi.org/10.3390/microorganisms11051308.</Citation></Reference><Reference><Citation>A. F. Ogata, C. A. Cheng, M. Desjardins, et al., “Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) Vaccine Antigen Detected in the Plasma of mRNA‐1273 Vaccine Recipients,” Clinical Infectious Diseases 74, no. 4 (2022): 715–718, https://doi.org/10.1093/cid/ciab465.</Citation></Reference><Reference><Citation>C. J. Michel, C. Mayer, O. Poch, and J. D. Thompson, “Characterization of Accessory Genes in Coronavirus Genomes,” Virology Journal 17, no. 1 (2020): 131, https://doi.org/10.1186/s12985‐020‐01402‐1.</Citation></Reference><Reference><Citation>C. A. Beaudoin, M. Bartas, A. Volna, P. Pecinka, and T. L. Blundell, “Are There Hidden Genes in DNA/RNA Vaccines?,” Frontiers in Immunology 13 (2022): 801915, https://doi.org/10.3389/fimmu.2022.801915.</Citation></Reference><Reference><Citation>M. C. Nunes and S. A. Madhi, “COVID‐19 Vaccines in Pregnancy,” Trends in Molecular Medicine 28, no. 8 (2022): 662–680, https://doi.org/10.1016/j.molmed.2022.04.012.</Citation></Reference><Reference><Citation>A. M. Kotlyar, O. Grechukhina, A. Chen, et al., “Vertical Transmission of Coronavirus Disease 2019: A Systematic Review and Meta‐Analysis,” American Journal of Obstetrics and Gynecology 224, no. 1 (2021): 35–53.e33, https://doi.org/10.1016/j.ajog.2020.07.049.</Citation></Reference><Reference><Citation>L. Hui, M. B. Marzan, D. L. Rolnik, et al., “Reductions in Stillbirths and Preterm Birth in COVID‐19‐Vaccinated Women: A Multicenter Cohort Study of Vaccination Uptake and Perinatal Outcomes,” American Journal of Obstetrics and Gynecology 228, no. 5 (2023): 585.e581–585.e516, https://doi.org/10.1016/j.ajog.2022.10.040.</Citation></Reference><Reference><Citation>S. E. Reznik, P. M. Vuguin, A. Cohen, et al., “SARS‐CoV‐2 Infection in Unvaccinated High‐Risk Pregnant Women in the Bronx, NY, USA Is Associated With Decreased Apgar Scores and Placental Villous Infarcts,” Biomolecules 13, no. 8 (2023), 1224, https://doi.org/10.3390/biom13081224.</Citation></Reference><Reference><Citation>O. Beharier, R. Plitman Mayo, T. Raz, et al., “Efficient Maternal to Neonatal Transfer of Antibodies Against SARS‐CoV‐2 and BNT162b2 mRNA COVID‐19 Vaccine,” Journal of Clinical Investigation 131, no. 13 (2021), e150319, https://doi.org/10.1172/JCI150319.</Citation></Reference><Reference><Citation>M. Norman, M. C. Magnus, J. Soderling, et al., “Neonatal Outcomes After COVID‐19 Vaccination in Pregnancy,” Journal of the American Medical Association 331, no. 5 (2024): 396–407, https://doi.org/10.1001/jama.2023.26945.</Citation></Reference><Reference><Citation>K. E. Fleming‐Dutra, L. H. Zauche, L. E. Roper, et al., “Safety and Effectiveness of Maternal COVID‐19 Vaccines Among Pregnant People and Infants,” Obstetrics and Gynecology Clinics of North America 50, no. 2 (2023): 279–297, https://doi.org/10.1016/j.ogc.2023.02.003.</Citation></Reference><Reference><Citation>S. Prasad, E. Kalafat, H. Blakeway, et al., “Systematic Review and Meta‐Analysis of the Effectiveness and Perinatal Outcomes of COVID‐19 Vaccination in Pregnancy,” Nature Communications 13, no. 1 (2022): 2414, https://doi.org/10.1038/s41467‐022‐30052‐w.</Citation></Reference><Reference><Citation>K. J. Gray, E. A. Bordt, C. Atyeo, et al., “COVID‐19 Vaccine Response in Pregnant and Lactating Women: A Cohort Study,” American Journal of Obstetrics and Gynecology 225, no. 3 (2021): 303. e1‐.e17, https://doi.org/10.1016/j.ajog.2021.03.023.</Citation></Reference><Reference><Citation>K. E. Salotto, W. C. Olson Jr., K. E. Pollack, et al., “A Nano‐Enhanced Vaccine for Metastatic Melanoma Immunotherapy,” Cancer Drug Resistance 5, no. 3 (2022): 829–845, https://doi.org/10.20517/cdr.2021.132.</Citation></Reference><Reference><Citation>E. Winstead, Can mRNA Vaccines Help Treat Cancer? National Cancer Institute, accessed May 7th, 2022, https://www.cancer.gov/news‐events/cancer‐currents‐blog/2022/mrna‐vaccines‐to‐treat‐cancer.</Citation></Reference><Reference><Citation>S. Ramaswamy, N. Tonnu, K. Tachikawa, et al., “Systemic Delivery of Factor IX Messenger RNA for Protein Replacement Therapy,” Proceedings of the National Academy of Sciences 114, no. 10 (2017): E1941–E1950, https://doi.org/10.1073/pnas.1619653114.</Citation></Reference><Reference><Citation>B. Truong, G. Allegri, X. B. Liu, et al., “Lipid Nanoparticle‐Targeted mRNA Therapy as a Treatment for the Inherited Metabolic Liver Disorder Arginase Deficiency,” Proceedings of the National Academy of Sciences 116, no. 42 (2019): 21150–21159, https://doi.org/10.1073/pnas.1906182116.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>